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OBJECTIVES: To assess the cost-effectiveness of three treat-
ments (tiotropium, salmeterol, and no treatment) in patients with
moderate chronic obstructive pulmonary disease (COPD).
METHODS: A Markov model with a time horizon of one year
was developed to evaluate the cost-effectiveness of three treat-
ments including i) tiotropium, ii) salmeterol, and iii) no treat-
ment, in patients with moderate COPD. A hypothetical cohort
of 100,000 subjects with moderate COPD with the following
characteristics were included in the model: mean age of 65 years,
smoking history of 50 pack years, and disease duration of 9.5
years. The efﬁcacy and withdrawal data was taken from pub-
lished randomized clinical trials of the treatments conducted in
patients with moderate COPD. The effectiveness measure was
exacerbations avoided per patient per year. Incremental cost-
effectiveness ratio (ICER) was calculated as additional cost per
patient to prevent one exacerbation, compared with the next
most expensive option. A payer’s perspective was used and only
direct costs were included in the study. Sensitivity analyses were
conducted to test the robustness of the baseline estimates and the
study assumptions. RESULTS: The mean annual costs for 
no treatment, salmeterol, and tiotropium groups were $392,
$1268.7 and $1408.6, respectively. The ICER of tiotropium
compared with no treatment group was $1830.46/exacerbation
avoided, while the ICER of salmeterol compared with no treat-
ment group was $2454.35/exacerbation avoided. Sensitivity
analysis results for study variables were stable over a wide range;
however the results were most sensitive to the compliance rates
of the drugs. CONCLUSION: In patients with moderate COPD,
tiotropium was more cost-effective than salmeterol and no treat-
ment strategy. The study helps demonstrate the cost-effectiveness
of new treatment interventions in COPD, which would assist
private payers in evaluating the role of costly, yet effective 
therapies.
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OBJECTIVES: Limited information is available about the rela-
tive beneﬁts of various COPD medication treatments on the out-
comes and treatment costs in a Medicaid population. The
objective was to compare the effects of initial medication regi-
mens on COPD-related and all-cause events (hospitalizations
and/or emergency department visits) and COPD-related and all-
cause costs for patients with COPD. METHODS: A historical
cohort of Texas Medicaid patients aged 40 to 65 years, with
COPD-related medical costs (ICD-9-CM = 491, 492, 496), 24
months of continuous enrollment (12 months pre and post), and
at least one prescription claim (index) for ipratropium (IPR),
inhaled corticosteroids (ICS), salmeterol (SAL) or ﬂuticasone
propionate/salmeterol (FSC) between September 1, 2000, and
December 31, 2003 were assessed. For analysis of events, Cox-
proportional hazards regression analyses were conducted con-
trolling for baseline factors and pre-index events. For analyses
of costs, a two-part model with logistic regression and general-
ized linear model (GLM) were used to adjust for baseline char-
acteristics and pre-index utilization and costs. RESULTS: A total
of 6793 patients were identiﬁed; IPR (n = 4213), ICS (n = 968),
SAL (n = 401) and FSC (n = 1211). EVENTS—Compared with
IPR, only FSC was associated with a signiﬁcantly lower risk of
any COPD-related event (HR 0.733 [95%CI 0.650–0.826]), 
and any all-cause events (HR 0.906 [95%CI 0.844–0.972]).
COSTS—Compared to IPR, total COPD-related costs were
similar in FSC and ICS, and reduced by $108 (p < 0.05) in the
SAL cohort. However, for total all-cause costs, signiﬁcant reduc-
tions were observed for FSC ($792, P < 0.05) and SAL ($1226,
p < 0.05) but not the ICS cohort. CONCLUSION: Compared to
the IPR cohort, the FSC cohort was 27% less likely to have a
COPD-related event, 10% less likely to have any all-cause event,
had similar total COPD-related costs, and had reduced all-cause
treatment costs in COPD patients, indicating that FSC is a cost-
effective initial maintenance therapy compared to IPR.
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OBJECTIVES: A longitudinal analysis of managed care claims
data was conducted to estimate the treatment effects of inhaled
corticosteroids (ICS) on medical costs. METHODS: Patients
with Chronic Obstructive Pulmonary Disease (COPD) (ICD-9-
CM: 491, 492 or 496), ages 40 years or older, who had 15
months continuous eligibility, and received both ICS and regular
inhaled bronchodilators (i.e., anticholinergics or long-acting
beta2-agonists) were selected from the claims database. Individ-
ual-level data on exposure status and costs were summarized for
monthly intervals from up to one-year before the initiation of
bronchodilators (“index date”) through a two-year follow-up
period. A ﬁxed-effects approach that accounted for potential
omitted variable biases was used to estimate incremental effects
of initiating ICS on medical costs. Interaction teams were
included to evaluate the timing of ICS treatment as well as
impact of patient age. RESULTS: A total of 10,271 COPD
patients were used in the analysis. After adjusting for time-
variant factors including use of rescue medications and having
conditions of asthma or congestive heart failure, ICS treatment
was associated with monthly cost reduction of $43 in COPD-
related medical services and $55 in all-cause medical services.
Moreover, a one-month delay of ICS initiation was associated
with an additional $2 to $3 per month in medical costs. The
largest cost reduction was observed among older COPD patients.
CONCLUSION: The ﬁndings support evidence that initiation of
ICS treatment earlier than the current guideline recommended
strategy would be beneﬁcial to prevent exacerbation risks and to
reduce overall medical costs from managed care perspective.
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OBJECTIVES: To evaluate the economic value of a new taste-
masked oral clarithromycin preparation (clarithromycin
SipTechnology) by estimating the amount of cost savings due to
its improved compliance compared to clarithromycin suspension
in children with respiratory tract infections (RTI) in Germany.
